ATE444286T1 - 2-phenylpropionsäurederivate und diese enthaltende pharmazeutische zusammensetzung - Google Patents
2-phenylpropionsäurederivate und diese enthaltende pharmazeutische zusammensetzungInfo
- Publication number
- ATE444286T1 ATE444286T1 AT05729779T AT05729779T ATE444286T1 AT E444286 T1 ATE444286 T1 AT E444286T1 AT 05729779 T AT05729779 T AT 05729779T AT 05729779 T AT05729779 T AT 05729779T AT E444286 T1 ATE444286 T1 AT E444286T1
- Authority
- AT
- Austria
- Prior art keywords
- treatment
- acid derivatives
- prevention
- pharmaceutical compositions
- compounds
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- YPGCWEMNNLXISK-UHFFFAOYSA-N hydratropic acid Chemical class OC(=O)C(C)C1=CC=CC=C1 YPGCWEMNNLXISK-UHFFFAOYSA-N 0.000 title 1
- 102000004890 Interleukin-8 Human genes 0.000 abstract 2
- 108090001007 Interleukin-8 Proteins 0.000 abstract 2
- 230000004913 activation Effects 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 abstract 2
- 229940096397 interleukin-8 Drugs 0.000 abstract 2
- 210000000440 neutrophil Anatomy 0.000 abstract 2
- 230000007170 pathology Effects 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 102100036166 C-X-C chemokine receptor type 1 Human genes 0.000 abstract 1
- 102100028989 C-X-C chemokine receptor type 2 Human genes 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 206010018364 Glomerulonephritis Diseases 0.000 abstract 1
- 101000947174 Homo sapiens C-X-C chemokine receptor type 1 Proteins 0.000 abstract 1
- 108010018951 Interleukin-8B Receptors Proteins 0.000 abstract 1
- 206010034277 Pemphigoid Diseases 0.000 abstract 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 abstract 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract 1
- 229940111131 antiinflammatory and antirheumatic product propionic acid derivative Drugs 0.000 abstract 1
- 208000000594 bullous pemphigoid Diseases 0.000 abstract 1
- 230000003399 chemotactic effect Effects 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 abstract 1
- 210000000265 leukocyte Anatomy 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 150000005599 propionic acid derivatives Chemical class 0.000 abstract 1
- 230000010410 reperfusion Effects 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/63—Esters of sulfonic acids
- C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
- C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04101202 | 2004-03-23 | ||
| PCT/EP2005/051302 WO2005090295A2 (en) | 2004-03-23 | 2005-03-21 | 2-phenylpropionic acid derivatives and pharmaceutical compositions containing them |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE444286T1 true ATE444286T1 (de) | 2009-10-15 |
Family
ID=34970877
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05729779T ATE444286T1 (de) | 2004-03-23 | 2005-03-21 | 2-phenylpropionsäurederivate und diese enthaltende pharmazeutische zusammensetzung |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US8039656B2 (de) |
| EP (1) | EP1776336B1 (de) |
| JP (1) | JP4871257B2 (de) |
| CN (2) | CN101912382B (de) |
| AT (1) | ATE444286T1 (de) |
| AU (1) | AU2005223402B2 (de) |
| CA (1) | CA2553705C (de) |
| CY (1) | CY1109687T1 (de) |
| DE (1) | DE602005016937D1 (de) |
| DK (1) | DK1776336T3 (de) |
| ES (1) | ES2333445T3 (de) |
| HR (1) | HRP20090681T1 (de) |
| ME (1) | ME01763B (de) |
| NO (1) | NO337685B1 (de) |
| PL (1) | PL1776336T3 (de) |
| PT (1) | PT1776336E (de) |
| RS (1) | RS51109B (de) |
| RU (1) | RU2375347C2 (de) |
| SI (1) | SI1776336T1 (de) |
| WO (1) | WO2005090295A2 (de) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1951663T3 (pl) * | 2005-11-24 | 2017-01-31 | Dompé Farmaceutici S.P.A. | Pochodne (R)-aryloalkiloaminowe i zawierające je kompozycje farmaceutyczne |
| DK2024329T3 (da) * | 2006-05-18 | 2013-11-04 | Dompe Spa | (2r)-2-[(4-sulfonyl)aminophenyl]propanamider og farmaceutiske sammensætninger indeholdende dem |
| PT2094638E (pt) | 2006-12-19 | 2012-11-20 | Dompe Spa | Ácidos 2-aril-fluoropropanóicos e derivados e composições farmacêuticas que os contêm |
| EP2166006A1 (de) * | 2008-09-18 | 2010-03-24 | Dompe' S.P.A. | 2-Arylpropionsäuren und -Derivate und pharmazeutische Zusammensetzungen, die diese enthalten |
| EP2308485A1 (de) | 2009-10-06 | 2011-04-13 | Dompé S.p.a. | Sulfonamide zur Diabetesprävention |
| EP2308484A1 (de) * | 2009-10-06 | 2011-04-13 | Dompé S.p.a. | Hemmer von CXCRL1/2 als Adjuvanzien bei der Transplantation von Langerhans-Zellen |
| EP2316820A1 (de) * | 2009-10-28 | 2011-05-04 | Dompe S.p.A. | Als Bradykinin-Rezeptorantagonisten nützliche 2-Arylpropionamid-Derivate und pharmazeutische Zusammensetzungen damit |
| MD480Z5 (ro) * | 2011-07-07 | 2012-09-30 | Эльвира АНДОН | Metodă de tratament al colitei ulceroase nespecifice acute |
| CN103159649B (zh) * | 2011-12-19 | 2016-03-09 | 天津市国际生物医药联合研究院 | 磺酰胺类化合物的制备及其应用 |
| CN103159650B (zh) * | 2011-12-19 | 2016-04-20 | 天津市国际生物医药联合研究院 | 芳香杂环磺酰胺类化合物的制备及其应用 |
| US10561676B2 (en) * | 2013-08-02 | 2020-02-18 | Syntrix Biosystems Inc. | Method for treating cancer using dual antagonists of CXCR1 and CXCR2 |
| US10046002B2 (en) | 2013-08-02 | 2018-08-14 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists |
| EP3117835A1 (de) | 2015-07-14 | 2017-01-18 | Dompé farmaceutici s.p.a. | Il-8-inhibitoren zur verwendung bei der behandlung bestimmter urologischen erkrankungen |
| JP7049254B2 (ja) * | 2016-01-15 | 2022-04-06 | ドンペ ファーマスーチシ ソシエタ ペル アチオニ | 化学療法で誘導される末梢神経障害の治療に使用するためのｉｌ－８阻害剤 |
| EP3192504A1 (de) | 2016-01-15 | 2017-07-19 | Dompé farmaceutici S.p.A. | Il-8-inhibitoren zur verwendung bei der behandlung von durch chemotherapie ausgelöster peripherer neuropathie |
| CN109890364B (zh) | 2016-10-03 | 2023-10-17 | 儿童医疗中心公司 | 糖尿病肾病的预防和治疗 |
| EP3342407A1 (de) * | 2017-01-03 | 2018-07-04 | Dompé farmaceutici S.p.A. | Il-8-inihibitoren zur verwendung bei der behandlung von urologischen erkrankungen |
| EP3409277A1 (de) | 2017-05-30 | 2018-12-05 | Dompé farmaceutici s.p.a. | Il-8-inhibitoren zur verwendung bei der behandlung und/oder prävention von bakteriellen sekundärinfektionen |
| EP3476390A1 (de) * | 2017-10-24 | 2019-05-01 | Dompé farmaceutici S.p.A. | Il-8-inhibitoren zur verwendung bei der behandlung von sarkomen |
| EP3498269A1 (de) | 2017-12-12 | 2019-06-19 | Dompé farmaceutici S.p.A. | C5ar-inhibitoren zur verwendung bei der behandlung von durch chemotherapie ausgelöstem iatrogenem schmerz |
| EP3868369A1 (de) | 2020-02-21 | 2021-08-25 | Dompe' Farmaceutici S.P.A. | Cxcl8-inhibitor und pharmazeutische zusammensetzung davon zur verwendung in der behandlung von krebsbedingter ermüdung |
| EP3868368A1 (de) | 2020-02-21 | 2021-08-25 | Dompe' Farmaceutici S.P.A. | Inhibitor der aktivität von cxcl8 (interleukin-8) und corticosteroidkombination und pharmazeutische zusammensetzung und verwendung davon |
| CA3176715A1 (en) | 2020-03-26 | 2021-09-30 | Dompe' Farmaceutici Spa | Cxcl8 inhibitors for use in the treatment of covid-19 |
| EP3884932A1 (de) | 2020-03-26 | 2021-09-29 | Dompe' Farmaceutici S.P.A. | Cxcl8-inhibitoren zur verwendung bei der behandlung von covid-19 |
| EP4008325A1 (de) | 2020-12-02 | 2022-06-08 | Dompe' Farmaceutici S.P.A. | Cxcl8-inhibitoren zur verwendung bei der behandlung von covid-19 |
| KR20230110751A (ko) * | 2020-11-05 | 2023-07-25 | 이칸 스쿨 오브 메디슨 엣 마운트 시나이 | 골수섬유증의 치료에 사용하기 위한 cxcr1/cxcr2 억제제 |
| EP4052702A1 (de) | 2021-03-04 | 2022-09-07 | Dompé farmaceutici S.p.a. | Cxcl8-inhibitor und dessen pharmazeutische zusammensetzung zur verwendung bei der behandlung von krampfanfällen |
| KR20230092100A (ko) * | 2021-12-16 | 2023-06-26 | 주식회사 동진쎄미켐 | 염 화합물 및 이를 포함하는 산확산 억제제, 포토레지스트 조성물 |
| EP4397305A1 (de) | 2023-01-05 | 2024-07-10 | Dompe' Farmaceutici S.P.A. | Cxcl8-inhibitoren zur verwendung bei der behandlung von augenschleimhaut-pemphigoid und/oder mundschleimhaut-pemphigoid |
| EP4563594A1 (de) | 2023-11-28 | 2025-06-04 | Dompe' Farmaceutici SpA | Cxcl8-inhibitoren zur verwendung bei der behandlung von tumoren mit niedrigem stroma-cav1-gehalt |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0964849B1 (de) * | 1997-01-29 | 2003-06-04 | Pfizer Inc. | Sulfonylharnstoff-derivate und ihre verwendung in der kontrolle der interleukin-1-aktivität |
| IT1303249B1 (it) | 1998-10-23 | 2000-11-06 | Dompe Spa | Alcune n-(2-aril-propionil)-solfonammidi e preparazionifarmaceutiche che le contengono. |
| IT1317826B1 (it) * | 2000-02-11 | 2003-07-15 | Dompe Spa | Ammidi, utili nell'inibizione della chemiotassi dei neutrofiliindotta da il-8. |
| ITMI20010395A1 (it) | 2001-02-27 | 2002-08-27 | Dompe Spa | Omega-amminoalchilammidi di acidi r-2-aril-propionici come inibitori della chemiotassi di cellule polimorfonucleate e mononucleate |
| ITMI20012025A1 (it) * | 2001-09-28 | 2003-03-28 | Dompe Spa | Sali di ammonio quaternari di omega-amminoalchilammidi di acidi r 2-aril-propionici e composizioni farmaceutiche che li contengono |
| ITMI20012434A1 (it) * | 2001-11-20 | 2003-05-20 | Dompe Spa | Acidi 2-aril-propionici e composizioni farmaceutiche che li contengono |
| DK1590314T3 (en) * | 2003-02-06 | 2015-11-02 | Dompé Farmaceutici S P A | 2-ARYL ACETIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| RU2375346C2 (ru) * | 2003-09-25 | 2009-12-10 | ДОМПЕ ФА.Р.МА С.п.А. | Амидины и их производные и содержащие их фармацевтические композиции |
-
2005
- 2005-03-21 PT PT05729779T patent/PT1776336E/pt unknown
- 2005-03-21 JP JP2007504413A patent/JP4871257B2/ja not_active Expired - Lifetime
- 2005-03-21 ES ES05729779T patent/ES2333445T3/es not_active Expired - Lifetime
- 2005-03-21 AT AT05729779T patent/ATE444286T1/de active
- 2005-03-21 HR HR20090681T patent/HRP20090681T1/hr unknown
- 2005-03-21 DK DK05729779.8T patent/DK1776336T3/da active
- 2005-03-21 US US10/592,572 patent/US8039656B2/en active Active
- 2005-03-21 CA CA2553705A patent/CA2553705C/en not_active Expired - Lifetime
- 2005-03-21 PL PL05729779T patent/PL1776336T3/pl unknown
- 2005-03-21 ME MEP-2009-568A patent/ME01763B/de unknown
- 2005-03-21 RS RSP-2009/0568A patent/RS51109B/sr unknown
- 2005-03-21 AU AU2005223402A patent/AU2005223402B2/en not_active Expired
- 2005-03-21 DE DE602005016937T patent/DE602005016937D1/de not_active Expired - Lifetime
- 2005-03-21 EP EP05729779A patent/EP1776336B1/de not_active Expired - Lifetime
- 2005-03-21 CN CN2010102609529A patent/CN101912382B/zh not_active Expired - Lifetime
- 2005-03-21 RU RU2006137272/04A patent/RU2375347C2/ru active
- 2005-03-21 CN CN200580008890XA patent/CN1934077B/zh not_active Expired - Lifetime
- 2005-03-21 SI SI200530869T patent/SI1776336T1/sl unknown
- 2005-03-21 WO PCT/EP2005/051302 patent/WO2005090295A2/en not_active Ceased
-
2006
- 2006-10-20 NO NO20064766A patent/NO337685B1/no unknown
-
2009
- 2009-12-18 CY CY20091101318T patent/CY1109687T1/el unknown
-
2011
- 2011-09-15 US US13/234,125 patent/US8293788B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE444286T1 (de) | 2-phenylpropionsäurederivate und diese enthaltende pharmazeutische zusammensetzung | |
| Berkhout et al. | CCR2: characterization of the antagonist binding site from a combined receptor modeling/mutagenesis approach | |
| NO20054672D0 (no) | Sulfonsyrer, derivater derav og farmasoytiske prepater omfattende slike forbindelser | |
| Cocco et al. | Synthesis of ibuprofen heterocyclic amides and investigation of their analgesic and toxicological properties | |
| NO20074641L (no) | 1-Acetic Acid-Indole Derivatives with PGD2 Antagonist Activity | |
| Schrøder et al. | The identification of AF38469: An orally bioavailable inhibitor of the VPS10P family sorting receptor Sortilin | |
| EA200701361A1 (ru) | Конденсированные производные пиразола и способы лечения с их помощью заболеваний, вызванных нарушением обмена веществ | |
| ATE463495T1 (de) | Oxadiazolylpyrazolopyrimidine als mglur2- antagonisten | |
| Le et al. | Optimization of novel 1-methyl-1 h-pyrazole-5-carboxamides leads to high potency larval development inhibitors of the barber’s pole worm | |
| Gilbert et al. | N-((8-Hydroxy-5-substituted-quinolin-7-yl)(phenyl) methyl)-2-phenyloxy/amino-acetamide inhibitors of ADAMTS-5 (Aggrecanase-2) | |
| Jeffries et al. | Discovery of VU6015929: a selective discoidin domain receptor 1/2 (DDR1/2) inhibitor to explore the role of DDR1 in antifibrotic therapy | |
| BR0214322A (pt) | ácidos 2-aril-propiÈnicos e composições farmacêuticas contendo os mesmos | |
| George et al. | Discovery of thieno [2, 3-c] pyridines as potent COT inhibitors | |
| EA200600879A1 (ru) | Тетразольные производные и способы лечения расстройств, связанных с метаболизмом, с их помощью | |
| Labadie et al. | Optimization of 5-(2, 6-dichlorophenyl)-3-hydroxy-2-mercaptocyclohex-2-enones as potent inhibitors of human lactate dehydrogenase | |
| NO20054017L (no) | 2-aryl-eddiksyrer, deres derivater og farmasoytisk sammensetninger som inneholder dem | |
| NO20080165L (no) | Alfa-(aryl-OR heteroaryl-metyl)-beta piperidinopropanamidforbindelser som ORL1-receptorantagonister | |
| Miller et al. | Synthesis and SAR of analogs of the M1 allosteric agonist TBPB. Part II: Amides, sulfonamides and ureas—the effect of capping the distal basic piperidine nitrogen | |
| Das et al. | Discovery and SAR of 2-amino-5-[(thiomethyl) aryl] thiazoles as potent and selective Itk inhibitors | |
| Skotnicki et al. | TNF-α converting enzyme (TACE) as a therapeutic target | |
| Yokokawa et al. | Recent advances in the discovery of non-peptidic direct renin inhibitors as antihypertensives: new patent applications in years 2000–2008 | |
| DE602006007210D1 (de) | Metaboliten aus 2-arylpropionsäure-derivaten und pharmazeutische zusammensetzungen damit | |
| Wei et al. | CCR5 receptor antagonists: Discovery and SAR study of guanylhydrazone derivatives | |
| Laliberté et al. | Discovery of a series of aryl-N-(3-(alkylamino)-5-(trifluoromethyl) phenyl) benzamides as TRPA1 antagonists | |
| Walker et al. | Identification of SD-0006, a potent diaryl pyrazole inhibitor of p38 MAP kinase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1776336 Country of ref document: EP |
|
| EEIH | Change in the person of patent owner |